BofA lowered the firm’s price target on Annexon (ANNX) to $8 from $9 and keeps a Buy rating on the shares. Following the company’s Q3 update, the firm lowered its gross pipeline value estimate to $150M from $300M and also notes that the company announced a $75M public offering.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon price target lowered to $8 from $9 at BofA
- Annexon Biosciences Completes Successful Public Offering
- Annexon 25.1M share Spot Secondary priced at $2.60
- Annexon announces $75M common stock, warrants offering
- Annexon Biosciences: Promising Advancements in Late-Stage Complement Inhibitors Drive Buy Rating